Company First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.85 ^USD	+1.06%		+9.62%	-32.14%

03-29	First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-14	Sector Update: Health Care Stocks Retreating Late Afternoon	MT

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Number of employees: 9

Managers	Title	Age	Since
James Sapirstein CEO	Chief Executive Officer	63	07/10/19
Sarah Romano DFI	Director of Finance/CFO	44	28/02/22
Amy Chandler CMP	Compliance Officer	56	-
Martin Krusin PRN	Corporate Officer/Principal	-	31/12/13

Members of the board	Title	Age	Since
Charles Casamento BRD	Director/Board Member	78	02/03/17
Ed Borkowski BRD	Director/Board Member	64	30/04/15
Alastair Riddell BRD	Director/Board Member	74	31/08/15
James Sapirstein CEO	Chief Executive Officer	63	07/10/19
Mary Coelho BRD	Director/Board Member	62	10/08/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,025,199	1,869,470 ( 92.31 %)	0	92.31 %

Name	Equities	%	Valuation
Armistice Capital LLC 3.854 %	78,061	3.854 %	213 107 $
James Sapirstein 1.832 %	37,105	1.832 %	101 297 $
Sarah Romano 0.9437 %	19,111	0.9437 %	52 173 $
Jack Syage 0.7604 %	15,400	0.7604 %	42 042 $
Tower Research Capital LLC 0.1400 %	2,836	0.1400 %	7 742 $
UBS Securities LLC 0.0759 %	1,537	0.0759 %	4 196 $
Chaitan S. Khosla 0.0217 %	440	0.0217 %	1 201 $
Wells Fargo Bank NA 0.000642 %	13	0.000642 %	35 $
Kathleen S. Wright Associates, Inc. 0.000049 %	1	0.000049 %	3 $
U.S. Bank Main Branch (363657) 0.000049 %	1	0.000049 %	3 $

Name	Equities	%	Valuation
Ed Borkowski -	48	-	131 $
James Sapirstein -	14	-	38 $

First Wave Biopharma, Inc.

777 Yamato Road Suite 502

33431, Boca Raton

+(561) 589-7020

http://www.firstwavebio.com

address First Wave BioPharma, Inc.(FWBI)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.85 USD

Average target price

36 USD

Spread / Average Target

+1,163.16%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
FIRST WAVE BIOPHARMA, INC.	-32.14%	5.77M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research